Literature DB >> 32213930

Alendronic Acid as Ionic Liquid: New Perspective on Osteosarcoma.

Sónia Teixeira1, Miguel M Santos2, Maria H Fernandes1,3, João Costa-Rodrigues1,4,5, Luís C Branco2.   

Abstract

Herein the quantitative synthesis of eight new mono- and dianionic Organic Salts and Ionic Liquids (OSILs) from alendronic acid (ALN) is reported by following two distinct sustainable and straightforward methodologies, according to the type of cation. The prepared ALN-OSILs were characterized by spectroscopic techniques and their solubility in water and biological fluids was determined. An evaluation of the toxicity towards human healthy cells and also human breast, lung and bone (osteosarcoma) cell lines was performed. Globally, it was observed that the monoanionic OSILs showed lower toxicity than the corresponding dianionic structures to all cell types. The highest cytotoxic effect was observed in OSILs containing a [C2OHMIM] cation, in particular [C2OHMIM][ALN]. The latter showed an improvement in IC50 values of ca. three orders of magnitude for the lung and bone cancer cell lines as well as fibroblasts in comparison with ALN. The development of OSILs with high cytotoxicity effect towards the tested cancer cell types, and containing an anti-resorbing molecule such as ALN may represent a promising strategy for the development of new pharmacological tools to be used in those pathological conditions.

Entities:  

Keywords:  API-OSILs; Active Pharmaceutical Ingredients; alendronic acid; anticancer drugs; ionic liquids

Year:  2020        PMID: 32213930     DOI: 10.3390/pharmaceutics12030293

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  6 in total

1.  Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans.

Authors:  Yogesh Sutar; Sophie R Fulton; Sagarkumar Paul; Sophie Altamirano; Susmit Mhatre; Hiwa Saeed; Pratikkumar Patel; Sudipta Mallick; Roopal Bhat; Vandana B Patravale; Harsh Chauhan; Kirsten Nielsen; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2021-09-01       Impact factor: 5.084

2.  Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2.

Authors:  Francisco Faísca; Vanessa Correia; Željko Petrovski; Luís C Branco; Helena Rebelo-de-Andrade; Miguel M Santos
Journal:  Pharmaceutics       Date:  2022-04-17       Impact factor: 6.525

3.  Antimicrobial Activities of Highly Bioavailable Organic Salts and Ionic Liquids from Fluoroquinolones.

Authors:  Miguel M Santos; Celso Alves; Joana Silva; Catarina Florindo; Alexandra Costa; Željko Petrovski; Isabel M Marrucho; Rui Pedrosa; Luís C Branco
Journal:  Pharmaceutics       Date:  2020-07-23       Impact factor: 6.321

4.  pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy.

Authors:  Silvia Tampucci; Lorenzo Guazzelli; Susi Burgalassi; Sara Carpi; Patrizia Chetoni; Andrea Mezzetta; Paola Nieri; Beatrice Polini; Christian Silvio Pomelli; Eleonora Terreni; Daniela Monti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

5.  Boosting Antimicrobial Activity of Ciprofloxacin by Functionalization of Mesoporous Silica Nanoparticles.

Authors:  Blanca de Juan Mora; Luís Filipe; Andreia Forte; Miguel M Santos; Celso Alves; Fernando Teodoro; Rui Pedrosa; Manuela Ribeiro Carrott; Luís C Branco; Sandra Gago
Journal:  Pharmaceutics       Date:  2021-02-05       Impact factor: 6.321

6.  HAP-Multitag, a PET and Positive MRI Contrast Nanotracer for the Longitudinal Characterization of Vascular Calcifications in Atherosclerosis.

Authors:  Juan Pellico; Irene Fernández-Barahona; Jesús Ruiz-Cabello; Lucía Gutiérrez; María Muñoz-Hernando; María J Sánchez-Guisado; Irati Aiestaran-Zelaia; Lydia Martínez-Parra; Ignacio Rodríguez; Jacob Bentzon; Fernando Herranz
Journal:  ACS Appl Mater Interfaces       Date:  2021-09-16       Impact factor: 9.229

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.